Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: results from the Netherlands Cancer Registry
A partir des données du registre néerlandais des cancers portant sur la période 2010-2014, cette étude analyse les traitements et la survie de patients atteints d'un cancer du poumon non à petites cellules de stade IIIb selon la classification internationale TNM-7 (43 762 patients)
Objectives : There is limited data on the pattern of care for locally advanced, clinical (c) IIIB non-small cell lung cancer (NSCLC) in the TNM-7 staging era. The primary aim of this study was to investigate national patterns of care and outcomes in the Netherlands, with a secondary focus on the use of surgery. Material and Methods : Data from patients treated for TNM-7 cIIIB NSCLC between 2010-2014, was extracted from the Netherlands Cancer Registry (NCR). Survival data was obtained from the automated Civil Registry. Results : 43.762 patients with NSCLC were recorded in the NCR during this 5-year period, with cIIIB accounting for 10% (n = 4.401). Clinical N2 (37%) and N3 (63%) nodal involvement was pathologically confirmed in 50.8%. The use of endobronchial ultrasound (EBUS) increased with time from 9% to 29% (p < 0.001), while the rate of pathological confirmation of N2 or N3 nodes increased from 44% to 54% (p < 0.001). 48% of patients received chemoradiotherapy (CRT), 19% chemotherapy (CT), RT in 10% and surgery in 2.2%. 22% received best supportive care (BSC). The percentage of patients treated with CRT decreased from 65% for patients aged <60 years to 13% for patients aged 80 years or older. Overall survival for surgery was 28 months, followed by CRT (19mths), CT (9mths), RT (8mths) and BSC (3mths). Conclusion : In the Netherlands, CRT is the most frequent treatment for cIIIB NSCLC in the TNM-7 era. The use of surgery is limited. Accurate staging requires specific attention and the scarce use of radical treatment in elderly patients merits further evaluation.